Literature DB >> 23954162

DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies.

Xing Hua1, Haiming Xu, Yaning Yang, Jun Zhu, Pengyuan Liu, Yan Lu.   

Abstract

Cancers are caused by the accumulation of genomic alterations. Driver mutations are required for the cancer phenotype, whereas passenger mutations are irrelevant to tumor development and accumulate through DNA replication. A major challenge facing the field of cancer genome sequencing is to identify cancer-associated genes with mutations that drive the cancer phenotype. Here, we describe a powerful and flexible statistical framework for identifying driver genes and driver signaling pathways in cancer genome-sequencing studies. Biological knowledge of the mutational process in tumors is fully integrated into our statistical models and includes such variables as the length of protein-coding regions, transcript isoforms, variation in mutation types, differences in background mutation rates, the redundancy of genetic code, and multiple mutations in one gene. This framework provides several significant features that are not addressed or naively obtained by previous methods. In particular, on the observation of low prevalence of somatic mutations in individual tumors, we propose a heuristic strategy to estimate the mixture proportion of chi-square distribution of likelihood ratio test (LRT) statistics. This provides significantly increased statistical power compared to regular LRT. Through a combination of simulation and analysis of TCGA cancer sequencing study data, we demonstrate high accuracy and sensitivity in our methods. Our statistical methods and several auxiliary bioinformatics tools have been incorporated into a computational tool, DrGaP. The newly developed tool is immediately applicable to cancer genome-sequencing studies and will lead to a more complete identification of altered driver genes and driver signaling pathways in cancer.
Copyright © 2013 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23954162      PMCID: PMC3769934          DOI: 10.1016/j.ajhg.2013.07.003

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  55 in total

1.  Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations.

Authors:  Daiki Miki; Michiaki Kubo; Atsushi Takahashi; Kyong-Ah Yoon; Jeongseon Kim; Geon Kook Lee; Jae Ill Zo; Jin Soo Lee; Naoya Hosono; Takashi Morizono; Tatsuhiko Tsunoda; Naoyuki Kamatani; Kazuaki Chayama; Takashi Takahashi; Johji Inazawa; Yusuke Nakamura; Yataro Daigo
Journal:  Nat Genet       Date:  2010-09-26       Impact factor: 38.330

2.  Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.

Authors:  Todd D Prickett; Xiaomu Wei; Isabel Cardenas-Navia; Jamie K Teer; Jimmy C Lin; Vijay Walia; Jared Gartner; Jiji Jiang; Praveen F Cherukuri; Alfredo Molinolo; Michael A Davies; Jeffrey E Gershenwald; Katherine Stemke-Hale; Steven A Rosenberg; Elliott H Margulies; Yardena Samuels
Journal:  Nat Genet       Date:  2011-09-25       Impact factor: 38.330

3.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

4.  Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.

Authors:  Kai Wang; Junsuo Kan; Siu Tsan Yuen; Stephanie T Shi; Kent Man Chu; Simon Law; Tsun Leung Chan; Zhengyan Kan; Annie S Y Chan; Wai Yin Tsui; Siu Po Lee; Siu Lun Ho; Anthony K W Chan; Grace H W Cheng; Peter C Roberts; Paul A Rejto; Neil W Gibson; David J Pocalyko; Mao Mao; Jiangchun Xu; Suet Yi Leung
Journal:  Nat Genet       Date:  2011-10-30       Impact factor: 38.330

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

7.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

8.  RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer.

Authors:  Tokuhiro Chano; Kaichiro Ikebuchi; Yasuko Ochi; Hitosuke Tameno; Yasuhiko Tomita; Yufen Jin; Hideo Inaji; Makoto Ishitobi; Koji Teramoto; Ichiro Nishimura; Kahori Minami; Hirokazu Inoue; Takahiro Isono; Masao Saitoh; Taketoshi Shimada; Yasuo Hisa; Hidetoshi Okabe
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

Review 9.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

10.  Identifying cancer driver genes in tumor genome sequencing studies.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2010-12-17       Impact factor: 6.937

View more
  29 in total

Review 1.  Precision medicine for metastatic breast cancer--limitations and solutions.

Authors:  Monica Arnedos; Cecile Vicier; Sherene Loi; Celine Lefebvre; Stefan Michiels; Herve Bonnefoi; Fabrice Andre
Journal:  Nat Rev Clin Oncol       Date:  2015-07-21       Impact factor: 66.675

2.  ZSCAN10 promotes cell proliferation, upregulates OCT4 expression, and activates Wnt/β-catenin signaling in glioma.

Authors:  Yuan Jiang; Hongming Huang; Xingen Zhu; Miaojing Wu; Minhua Ye; Bing Xiao; Cong Yu; Hua Fang; Feng Liu; Shigang Lv
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

3.  DriverML: a machine learning algorithm for identifying driver genes in cancer sequencing studies.

Authors:  Yi Han; Juze Yang; Xinyi Qian; Wei-Chung Cheng; Shu-Hsuan Liu; Xing Hua; Liyuan Zhou; Yaning Yang; Qingbiao Wu; Pengyuan Liu; Yan Lu
Journal:  Nucleic Acids Res       Date:  2019-05-07       Impact factor: 16.971

Review 4.  Computational methods and resources for the interpretation of genomic variants in cancer.

Authors:  Rui Tian; Malay K Basu; Emidio Capriotti
Journal:  BMC Genomics       Date:  2015-06-18       Impact factor: 3.969

5.  Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.

Authors:  Runjun D Kumar; Adam C Searleman; S Joshua Swamidass; Obi L Griffith; Ron Bose
Journal:  Bioinformatics       Date:  2015-07-25       Impact factor: 6.937

6.  Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.

Authors:  Junfei Zhao; Feixiong Cheng; Yuanyuan Wang; Carlos L Arteaga; Zhongming Zhao
Journal:  Mol Cell Proteomics       Date:  2015-12-09       Impact factor: 5.911

7.  An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer.

Authors:  Jasmine Foo; Lin L Liu; Kevin Leder; Markus Riester; Yoh Iwasa; Christoph Lengauer; Franziska Michor
Journal:  PLoS Comput Biol       Date:  2015-09-17       Impact factor: 4.475

8.  Characterization and identification of hidden rare variants in the human genome.

Authors:  Alberto Magi; Romina D'Aurizio; Flavia Palombo; Ingrid Cifola; Lorenzo Tattini; Roberto Semeraro; Tommaso Pippucci; Betti Giusti; Giovanni Romeo; Rosanna Abbate; Gian Franco Gensini
Journal:  BMC Genomics       Date:  2015-04-24       Impact factor: 3.969

Review 9.  Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine.

Authors:  Benjamin J Raphael; Jason R Dobson; Layla Oesper; Fabio Vandin
Journal:  Genome Med       Date:  2014-01-30       Impact factor: 11.117

10.  Identification of collaborative driver pathways in breast cancer.

Authors:  Yang Liu; Zhenjun Hu
Journal:  BMC Genomics       Date:  2014-07-17       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.